Motif Neurotech Receives FDA Approval for First Clinical Trial of Wireless Brain Implant for Treatment-Resistant Depression

Motif NeurotechSearch company announced that the U.S. Food and Drug Administration has approved an Investigational Device Exemption (IDE) for the RESONATE Early Feasibility Study, marking a significant milestone for the Houston-based brain-computer interface company. The approval allows the company to begin testing its XCS SystemSearch drug, a wirelessly-powered brain implant designed to treat adults with treatment-resistant depressionSearch disease who have not found relief from two or more medications.

The approval comes just four years after Motif's founding, making it the fastest implantable BCI company to move from founding to IDE approval with a novel device. "We founded Motif to build neural devices that give everyone suffering from a mental health condition the opportunity at a better life. I am incredibly proud of our team, and grateful for this opportunity to advance our mission," said Jacob Robinson, Co-founder and CEO of Motif NeurotechSearch company.

Novel Approach to Brain Stimulation

The XCS SystemSearch drug represents a unique approach to treating depressionSearch disease through brain stimulation. Unlike traditional transcranial magnetic stimulation (TMS) methods that scientists have used for decades to treat depression, Motif's device offers a wireless, implantable solution. The blueberry-sized device is implanted in the skull and activated by wearing what resembles a baseball hat, which wirelessly powers the implant to deliver gentle electrical stimulation to specific brain regions.

"With XCS therapy, we seek to achieve an optimal balance of effectiveness and non-invasiveness," explained Sunil Sheth, M.D., Co-founder of Motif and Associate Professor of Neurology at UTHealth Houston. "The device's ability to stimulate and address dysfunctional brain circuitsSearch term while avoiding direct contact with the brain will hopefully lead to safe and durable symptom improvement, in a form factor that patients find acceptable."

Addressing Critical Unmet Need

The RESONATE study targets a significant patient population with limited treatment options. Nearly 3 million Americans live with treatment-resistant depressionSearch disease, most of whom have exhausted available treatments without finding lasting relief. "Treatment-resistant depression is one of the leading causes of disability and suicide in the U.S. and worldwide. Individuals with this condition have often tried a long list of medications and therapies and are still suffering," said Sameer Sheth, M.D., Ph.D., Professor of Neurosurgery at Baylor College of MedicineSearch company, Co-founder of Motif, and Principal Investigator for the RESONATE study.

Multi-Center Clinical Trial

The RESONATE early feasibility study will assess both safety and viability of the wirelessly-powered XCS SystemSearch drug across eight leading medical institutions: Baylor College of MedicineSearch company, Massachusetts General BrighamSearch company, Emory HealthcareSearch company, UT Health HoustonSearch company, University of IowaSearch company, University of Utah HealthSearch company, New York UniversitySearch company, and Brain Health ConsultantsSearch company in Houston.

The study represents a potential paradigm shift in how patients with treatment-resistant depressionSearch disease might manage their condition. Robinson's vision includes patients incorporating the device activation into their daily routine - waking up, brushing teeth, washing face, and putting on the lifesaving baseball hat that would activate the implanted device to deliver therapeutic brain stimulation.